[1] |
Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M.tuberculosis? A TBNET consensus statement. Eur Respir J, 2009, 33(5):956-973. doi: 10.1183/09031936.00120908.
doi: 10.1183/09031936.00120908
pmid: 19407047
|
[2] |
World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention, tuberculosis preventive treatment. Geneva:World Health Organization, 2020.
|
[3] |
World Health Organization. Global tuberculosis report 2020. Geneva:World Health Organization, 2020.
|
[4] |
Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician, 2014, 89(11):889-896.
pmid: 25077395
|
[5] |
Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: asystematic review and individual-participant meta-analysis. Lancet, 2020, 395(10228):973-984. doi: 10.1016/S0140-6736(20)30166-5.
doi: 10.1016/S0140-6736(20)30166-5
URL
|
[6] |
World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019.
|
[7] |
李果, 庞先琼, 徐华, 等. 潜伏性结核感染诊治进展. 中国防痨杂志, 2021, 43(1):91-95. doi: 10.3969/j.issn.1000-6621.2021.01.017.
doi: 10.3969/j.issn.1000-6621.2021.01.017
|
[8] |
成诗明, 王国治, 王黎霞, 等. 结核菌素皮肤试验使用指导手册. 北京: 人民卫生出版社, 2014.
|
[9] |
Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet, 2000, 356(9235):1099-1104. doi: 10.1016/S0140-6736(00)02742-2.
doi: 10.1016/S0140-6736(00)02742-2
pmid: 11009160
|
[10] |
Edwards A, Gao Y, Allan RN, et al. Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis. Thorax, 2017, 72(10):946-949. doi: 10.1136/thoraxjnl-2016-209397.
doi: 10.1136/thoraxjnl-2016-209397
URL
|
[11] |
中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/j.issn.1000-6621.2020.08.001.
doi: 10.3969/j.issn.1000-6621.2020.08.001
|
[12] |
卢水华, 陆伟. 新型结核菌素皮肤试验使用手册. 北京: 人民卫生出版社, 2021.
|
[13] |
何翼君, 张浩然, 辛赫男, 等. 结核菌素皮肤试验的应用及其优化. 中国防痨杂志, 2021, 43(3):204-210. doi: 10.3969/j.issn.1000-6621.2021.03.003.
doi: 10.3969/j.issn.1000-6621.2021.03.003
|
[14] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09.
|
[15] |
Aggerbeck H, Ruhwald M, Hoff ST, et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. Int J Tuberc Lung Dis, 2019, 23(1):38-44. doi: 10.5588/ijtld.18.0137.
doi: 10.5588/ijtld.18.0137
pmid: 30572979
|
[16] |
Abubakar I, Jackson C, Rangaka MX. C-Tb: a latent tuberculosis skin test for the 21st century? Lancet Respir Med, 2017, 5(4):236-237. doi: 10.1016/S2213-2600(17)30012-7.
doi: 10.1016/S2213-2600(17)30012-7
URL
|
[17] |
Starshinova A, Dovgalyk I, Malkova A, et al. Recombinant tuberculosis allergen (Diaskintest®) in tuberculosis diagnostic in Russia (meta-analysis). Int J Mycobacteriol, 2020, 9(4):335-346. doi: 10.4103/ijmy.ijmy_131_20.
doi: 10.4103/ijmy.ijmy_131_20
pmid: 33323648
|
[18] |
都伟欣, 韦芬, 卢锦标, 等. 冻干重组结核杆菌融合蛋白(EC)原液效力评价用国家参考品的初步建立. 中国防痨杂志, 2020, 42(8):826-831. doi: 10.3969/j.issn.1000-6621.2020.08.009.
doi: 10.3969/j.issn.1000-6621.2020.08.009
|
[19] |
张凯, 沈小兵, 陶立峰, 等. 重组结核杆菌融合蛋白(EC)产品质量标准的建立. 中国防痨杂志, 2020, 42(8):814-820. doi: 10.3969/j.issn.1000-6621.2020.08.007.
doi: 10.3969/j.issn.1000-6621.2020.08.007
|
[20] |
张凯, 陶立峰, 韦芬, 等. 重组结核杆菌融合蛋白(EC)的免疫特性和临床前安全性研究. 中国防痨杂志, 2020, 42(8):807-813. doi: 10.3969/j.issn.1000-6621.2020.08.006.
doi: 10.3969/j.issn.1000-6621.2020.08.006
|
[21] |
中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02.
|
[22] |
World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update. Geneva:World Health Organization, 2019.
|
[23] |
刘二勇, 成诗明, 赖钰基, 等. 结核病预防性治疗研究进展. 中国防痨杂志, 2014, 36(1):59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013.
doi: 10.3969/j.issn.1000-6621.2014.01.013
|
[24] |
艾静文, 阮巧玲, 张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展. 中国防痨杂志, 2015, 37(1):80-85. doi: 10.3969/j.issn.1000-6621.2015.01.015.
doi: 10.3969/j.issn.1000-6621.2015.01.015
|
[25] |
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982, 60(4):555-564.
|
[26] |
World Health Organization. Global tuberculosis report 2018. Geneva:World Health Organization, 2018.
|
[27] |
Mohammadzadeh R, Ghazvini K, Farsiani H, et al. Mycobacterium tuberculosis extracellular vesicles: exploitation for vaccine technology and diagnostic methods. Crit Rev Microbiol, 2021, 47(1):13-33. doi: 10.1080/1040841X.2020.1830749.
doi: 10.1080/1040841X.2020.1830749
pmid: 33044878
|
[28] |
Myllymäki H, Niskanen M, Luukinen H, et al. Identification of protective postexposure mycobacterial vaccine antigens using an immunosuppression-based reactivation model in the zebrafish. Dis Model Mech, 2018, 11(3):dmm033175. doi: 10.1242/dmm.033175.
doi: 10.1242/dmm.033175
|